PMID- 34432617
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 70
IP  - 6S
DP  - 2021 Jul
TI  - Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of 
      SGLT-2 Inhibitors.
PG  - S1-S6
LID - 10.12788/jfp.0216 [doi]
AB  - At the end of the activity, participants will be able to: * Identify how heart 
      failure (HF), chronic kidney disease (CKD), and type 2 diabetes mellitus (T2DM) 
      and associated cardiovascular (CV) risks are interconnected. * Initiate 
      guideline-recommended therapy to reduce CV risk in patients with HF, CKD, and/or 
      T2DM. * Apply evidence for sodium-glucose cotransporter-2 inhibitors (SGLT-2 
      inhibitors) to clinical practice, based on recent and emerging trials. * Review 
      evidence suggesting increased incidence and severity of COVID-19 infection in 
      patients with diabetes.
FAU - Reid, Timothy
AU  - Reid T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Cardiovascular Diseases/*drug therapy/*prevention & control
MH  - Cardiovascular System/drug effects
MH  - Diabetes Mellitus, Type 2/drug therapy/prevention & control
MH  - Diabetic Cardiomyopathies/drug therapy/prevention & control
MH  - Diabetic Nephropathies/drug therapy/prevention & control
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
MH  - Treatment Outcome
EDAT- 2021/08/26 06:00
MHDA- 2021/09/02 06:00
CRDT- 2021/08/25 17:19
PHST- 2021/08/25 17:19 [entrez]
PHST- 2021/08/26 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
AID - jfp.0216 [pii]
AID - 10.12788/jfp.0216 [doi]
PST - ppublish
SO  - J Fam Pract. 2021 Jul;70(6S):S1-S6. doi: 10.12788/jfp.0216.